Drimva

Tempus

Director of Data & AI Partnerships, Life Sciences

$140K–$210K

Chicago +3 · Director · Full-time · Posted Oct 20, 2026

Location
Chicago
Boston
Redwood City
New York City
Experience
Minimum 5+ years; oncology experience (3+ years) and experience with life sciences service companies (5+ years) preferred.
Education
Bachelor degree in a Science or Business discipline; advanced degree (MBA, PhD or Healthcare certification) desired.

About the job

Develops strategic partnerships and account growth with pharmaceutical and biotechnology clients, using Tempus data and AI products to advance their research, clinical, and commercial programs.

What you'll do

  • Develop global account strategies, executive relationships, and revenue growth across assigned accounts.
  • Negotiate and manage complex contracts, coordinating cross-functional teams to deliver client value.
  • Identify opportunities to apply Tempus’s platform and develop impactful client case studies.

What they ask for

  • At least 5 years in business development, sales, and/or consulting in the life sciences sector as a lead account and relationship manager for Pharma/Biotech.
  • Knowledge of drug development and/or oncology.
  • Proven success navigating complex client organizations and negotiating and closing large, multi-year deals.
  • Strong understanding of molecular and real-world data and artificial intelligence in drug discovery.

Nice to have

  • Preferably 3+ years working on oncology assets or supporting projects in this space.
  • Preferably 5+ years working with companies serving life sciences in Research & Development and/or Real World Data; advanced degree or healthcare certification desired.

Pay

USD $140,000-$210,000 base salary (CHI); USD $140,000-$210,000 base salary (NYC/SF)

Tools

Tempus platform, multimodal datasets, foundation models, Real World Data

AI focus

Uses Tempus data, foundation models, and AI products to inform R&D decisions, improve trial technical success, and uncover insights for drug development.

Model-written summary · the original posting is authoritative

First seen Oct 28, 2026 · Last verified Nov 5, 2026 (UTC)